Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance

Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9

(2011) Andrea G. S. Buggins et al.   BRITISH JOURNAL OF HAEMATOLOGY

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

(2010) M. Buchner et al.   BLOOD

The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies

(2010) Maike Buchner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY

Antigenic Modulation and Rituximab Resistance

(2010) Ronald P. Taylor et al.   SEMINARS IN HEMATOLOGY

Rituximab inhibits B-cell receptor signaling

(2009) S. Kheirallah et al.   BLOOD

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

(2009) J. A. Burger et al.   BLOOD

Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting

(2009) Antonina V. Kurtova et al.   BLOOD

CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival

(2009) A. Zucchetto et al.   CANCER RESEARCH

Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG

(2009) A. K. Ghosh et al.   CLINICAL CANCER RESEARCH

Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions

(2009) M. I. Vega et al.   CLINICAL CANCER RESEARCH

The role of natalizumab in hematopoietic stem cell mobilization

(2009) Frank Neumann et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

(2008) Z. Zeng et al.   BLOOD

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

(2008) Tait D. Shanafelt et al.   BRITISH JOURNAL OF HAEMATOLOGY

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

(2008) A. Martin et al.   HAEMATOLOGICA

CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia

(2008) D. Rossi et al.   HAEMATOLOGICA

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

(2008) M. Krumbholz et al.   NEUROLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD38 at the junction between prognostic marker and therapeutic target

(2008) Silvia Deaglio et al.   TRENDS IN MOLECULAR MEDICINE